Antipsychotics

Johnson & Johnson Subsidiary Loses Drug-labeling Suit

The state of Arkansas won the ruling in its suit alleging the antipsychotic Risperdal included insufficient risk information in inserts and labels.

LITTLE ROCK, Arkansas — A Johnson & Johnson subsidiary downplayed and hid risks associated with the antipsychotic drug Risperdal, a jury determined Tuesday in Arkansas' billion-dollar lawsuit against Janssen Pharmaceuticals Inc.

Attorney General Dustin McDaniel's office is seeking fines of at least $1.2 billion for the 250,000 Risperdal prescriptions a state health coverage program paid over more than three years. The penalty will be decided Wednesday.

Your rating: None Average: 4 (1 vote)
Syndicate content